Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| MacroGenics Inc | MGNX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 15.70 | 07:34:27 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 15.70 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 4.29 - 21.88 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 15.70 | USD |
MacroGenics (MGNX) Options Flow Summary
MacroGenics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 980.18M | 62.43M | - | 58.75M | -9.06M | -0.15 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
MacroGenics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MGNX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 15.99 | 16.585 | 14.94 | 15.77 | 729,096 | -0.29 | -1.81% |
| 1 Month | 14.74 | 19.5408 | 12.82 | 16.85 | 1,412,128 | 0.96 | 6.51% |
| 3 Months | 14.40 | 21.88 | 12.82 | 17.18 | 1,572,182 | 1.30 | 9.03% |
| 6 Months | 4.91 | 21.88 | 4.76 | 14.40 | 1,134,366 | 10.79 | 219.76% |
| 1 Year | 6.70 | 21.88 | 4.29 | 11.50 | 835,536 | 9.00 | 134.33% |
| 3 Years | 34.85 | 36.4804 | 2.13 | 11.14 | 795,680 | -19.15 | -54.95% |
| 5 Years | 16.48 | 36.4804 | 2.13 | 15.28 | 841,177 | -0.78 | -4.73% |
MacroGenics Description
| Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them. |
